Quick Answer
Ginkgo Bioworks Holdings, Inc. reported Total Revenue of $170.16 million for fiscal year 2025.
Ginkgo Bioworks Holdings, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $170.16M -25.1% |
$227.04M -9.7% |
$251.46M -47.4% |
$477.71M +52.2% |
$313.84M +309.4% |
$76.66M +41.5% |
| Revenue (ASC 606) | $170.16M -25.1% |
$227.04M -9.7% |
$251.46M -47.4% |
$477.71M +52.2% |
$313.84M +309.4% |
$76.66M +41.5% |
| Net Income | -$312.76M +42.8% |
-$547.03M +38.7% |
-$892.87M +57.6% |
-$2.10B -15.0% |
-$1.83B -1345.4% |
-$126.61M -6.1% |
| Diluted EPS | -$5.64 +46.5% |
-$10.54 +42.6% |
-$18.37 +63.4% |
-$50.20 -3511.5% |
-$1.39 -1290.0% |
-$0.10 +0.0% |
| Total Assets | $1.12B -18.7% |
$1.38B -17.3% |
$1.67B -34.4% |
$2.54B +22.6% |
$2.07B +206.7% |
$675.15M |
| Cash and Equivalents | $167.20M -70.2% |
$561.57M -40.5% |
$944.07M -28.3% |
$1.32B -15.1% |
$1.55B +307.0% |
$380.80M -23.1% |
| Stockholders Equity | $508.59M -29.0% |
$716.06M -34.7% |
$1.10B -36.8% |
$1.74B +15.3% |
$1.51B +226.3% |
$461.38M -8.1% |
| R&D Expense | $243.77M -42.5% |
$424.06M -27.0% |
$580.62M -44.8% |
$1.05B -8.4% |
$1.15B +619.6% |
$159.77M +65.9% |
| Operating Income | -$315.28M +43.7% |
-$559.76M +35.2% |
-$864.41M +60.9% |
-$2.21B -20.8% |
-$1.83B -1234.4% |
-$137.03M -91.4% |
| Shares Outstanding | 58.21M +7.1% |
54.37M +8.7% |
50.03M -97.4% |
1.89B +17.4% |
1.61B +25.1% |
1.29B |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $38.84M | -56.4% | -21.7% |
| Revenue (ASC 606) | September 30, 2025 | $38.84M | -56.4% | -21.7% |
| Net Income | September 30, 2025 | -$80.75M | -43.2% | -43.2% |
| Diluted EPS | September 30, 2025 | -$1.45 | -34.3% | -31.8% |
| Total Assets | September 30, 2025 | $1.19B | -19.7% | -3.4% |
| Cash and Equivalents | September 30, 2025 | $111.06M | -82.0% | -45.4% |
| Stockholders Equity | September 30, 2025 | $559.78M | -29.8% | -8.7% |
| R&D Expense | September 30, 2025 | $69.35M | -9.9% | +29.9% |
| Operating Income | September 30, 2025 | -$90.02M | -63.1% | -37.3% |
| Shares Outstanding | September 30, 2025 | 56.84M | +7.1% | +2.5% |
- Ginkgo Bioworks Holdings, Inc. reported Total Revenue of $170.16 million for fiscal year 2025.
- Ginkgo Bioworks Holdings, Inc. showed a decrease of -25.1% in Total Revenue compared to the prior fiscal year.
- Ginkgo Bioworks Holdings, Inc. reported Revenue (ASC 606) of $170.16 million for fiscal year 2025.
- Ginkgo Bioworks Holdings, Inc. showed a decrease of -25.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Ginkgo Bioworks Holdings, Inc. reported Net Income of -$312.76 million for fiscal year 2025.
- Ginkgo Bioworks Holdings, Inc. showed an increase of +42.8% in Net Income compared to the prior fiscal year.
- Ginkgo Bioworks Holdings, Inc. reported Diluted EPS of $5.64 per share (loss) for fiscal year 2025.
- Ginkgo Bioworks Holdings, Inc. showed an increase of +46.5% in Diluted EPS compared to the prior fiscal year.
- Ginkgo Bioworks Holdings, Inc. reported Total Assets of $1.12 billion for fiscal year 2025.
- Ginkgo Bioworks Holdings, Inc. showed a decrease of -18.7% in Total Assets compared to the prior fiscal year.
- Ginkgo Bioworks Holdings, Inc. reported Cash and Equivalents of $167.20 million for fiscal year 2025.
- Ginkgo Bioworks Holdings, Inc. showed a decrease of -70.2% in Cash and Equivalents compared to the prior fiscal year.
- Ginkgo Bioworks Holdings, Inc. reported Stockholders Equity of $508.59 million for fiscal year 2025.
- Ginkgo Bioworks Holdings, Inc. showed a decrease of -29.0% in Stockholders Equity compared to the prior fiscal year.
- Ginkgo Bioworks Holdings, Inc. reported R&D Expense of $243.77 million for fiscal year 2025.
- Ginkgo Bioworks Holdings, Inc. showed a decrease of -42.5% in R&D Expense compared to the prior fiscal year.
- Ginkgo Bioworks Holdings, Inc. reported Operating Income of -$315.28 million for fiscal year 2025.
- Ginkgo Bioworks Holdings, Inc. showed an increase of +43.7% in Operating Income compared to the prior fiscal year.
- Ginkgo Bioworks Holdings, Inc. reported Shares Outstanding of 58.21 million shares for fiscal year 2025.
- Ginkgo Bioworks Holdings, Inc. showed an increase of +7.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: